Real-World Outcomes of Sevabertinib in HER2-Mutant Advanced NSCLC: A Bidirectional Cohort Study
Real-World Efficacy and Safety of Sevabertinib as Second-Line or Later-Line Therapy in Patients With HER2-Mutant Advanced Non-Small Cell Lung Cancer: An Observational, Bidirectional Cohort Study
This is a single-center, observational, bidirectional cohort study evaluating the real-world effectiveness, safety, and quality of life associated with sevabertinib in Chinese adults with HER2-mutant advanced non-small cell lung cancer receiving sevabertinib as second-line or later-line therapy. The study will include both retrospectively identified patients and prospectively enrolled patients. The primary objective is to evaluate real-world progression-free survival. Additional assessments include tumor response, overall survival, safety, and patient-reported quality of life.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Yi XIANG
- 전화번호: +86-13816967846
- 이메일: xiangyiht@163.com
연구 장소
-
-
Hainan
-
Qionghai, Hainan, 중국, 571400
- 모병
- Ruijin-Hainan Hospital, Shanghai Jiao Tong University School of Medicine (Hainan Boao Research Hospital)
-
연락하다:
- Yi XIANG
- 전화번호: +86-13816967846
- 이메일: xiangyiht@163.com
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Adult Chinese patients with unresectable locally advanced or metastatic non-squamous NSCLC harboring a documented HER2 (ERBB2) TKD activating mutation who receive sevabertinib as second-line or later-line therapy in routine clinical practice. The study includes both retrospectively identified patients and prospectively enrolled patients.
설명
Inclusion Criteria:
- Age ≥18 years at the index date.
- Unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
- Documented HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutation.
- Received at least one prior systemic therapy for advanced NSCLC. Prior HER2-targeted antibody-drug conjugate (ADC) therapy is permitted, whereas prior HER2-targeted tyrosine kinase inhibitor (TKI) therapy is not permitted.
- For retrospectively included participants, sufficient baseline clinical, treatment, and prior follow-up data are available.
- Sevabertinib treatment has been determined by the treating physician based on clinical practice, or the participant has already initiated sevabertinib at screening.
Exclusion Criteria:
- History of Grade 3 or higher interstitial lung disease (ILD), or evidence of any clinically active ILD.
- Uncontrolled comorbid diseases or conditions, including but not limited to decompensated respiratory, cardiac, hepatic, or renal disease; ongoing or active infection, including active clinical tuberculosis; renal transplantation; or psychiatric/social conditions that may limit study compliance.
- Unstable brain metastases.
- Inability to comply with the study for any reason.
- Receipt of another unapproved investigational drug or non-drug treatment within 30 days before the index date or during the observation period.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: OTHER
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
개입 / 치료개입 / 치료 |
|---|---|
|
Sevabertinib-Treated Cohort
Adult Chinese patients with HER2-mutant advanced non-small cell lung cancer receiving sevabertinib as second-line or later-line therapy in routine clinical practice. Treatment with sevabertinib is determined by the treating physician and is not assigned by the study protocol. |
Sevabertinib is administered as part of routine clinical care, generally at a dose of 20 mg orally twice daily with food until disease progression or unacceptable toxicity, according to the treating physician's clinical judgment. Treatment is not assigned by the study protocol. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Real-World Progression-Free Survival (rwPFS)
기간: From the first dose of sevabertinib until the first documented disease progression or death from any cause, whichever occurs first, assessed up to 12 months.
|
rwPFS is defined as the time from the first dose of sevabertinib to the first documented disease progression or death from any cause, whichever occurs first. |
From the first dose of sevabertinib until the first documented disease progression or death from any cause, whichever occurs first, assessed up to 12 months.
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Investigator-Assessed Real-World Objective Response Rate (rwORR)
기간: From the first dose of sevabertinib through the last available tumor response assessment, up to 12 months.
|
rwORR is defined as the proportion of evaluable participants whose best overall response is complete response (CR) or partial response (PR), as assessed by the investigator according to RECIST version 1.1. |
From the first dose of sevabertinib through the last available tumor response assessment, up to 12 months.
|
|
Investigator-Assessed Real-World Disease Control Rate (rwDCR)
기간: From the first dose of sevabertinib through the last available tumor response assessment, up to 12 months.
|
rwDCR is defined as the proportion of evaluable participants who achieve CR, PR, or stable disease (SD). Confirmed and unconfirmed best overall responses will be analyzed separately. |
From the first dose of sevabertinib through the last available tumor response assessment, up to 12 months.
|
|
6-Month and 12-Month Progression-Free Survival Rates
기간: At 6 months and 12 months after the first dose of sevabertinib.
|
The probabilities of participants being alive and free from disease progression at 6 months and 12 months after the first dose of sevabertinib. |
At 6 months and 12 months after the first dose of sevabertinib.
|
|
Incidence of Treatment-Related Adverse Events
기간: From the first dose of sevabertinib through the last available safety assessment, up to 12 months.
|
The incidence of treatment-related adverse events of any grade and Grade 3 or higher will be assessed. Adverse events will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 6.0. |
From the first dose of sevabertinib through the last available safety assessment, up to 12 months.
|
|
Change From Baseline in EORTC QLQ-C30 Scores
기간: Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.
|
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) assesses cancer-related quality of life. Scores for each scale range from 0 to 100. Higher functional and global health status/quality-of-life scores indicate better functioning or quality of life, whereas higher symptom scores indicate worse symptoms. |
Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.
|
|
Change From Baseline in NSCLC-SAQ Total Score
기간: Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.
|
The Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) assesses NSCLC-related symptoms. The total score ranges from 0 to 20, with higher scores indicating greater symptom severity. |
Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.
|
|
Change From Baseline in EQ-5D-5L Index Score
기간: Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.
|
The EuroQol 5-Dimension 5-Level (EQ-5D-5L) assesses overall health status across five dimensions. Using the Chinese value set, index scores range from -0.391 to 1.000, with higher scores indicating better health status. |
Baseline and at follow-up assessments through 12 months after the first dose of sevabertinib.
|
공동 작업자 및 조사자
협력자
협력자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- RWS2026-003
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Individual participant data (IPD) are not planned to be shared with external researchers because the study uses sensitive clinical data derived from medical records and follow-up. Study data are de-identified and managed under applicable confidentiality, privacy, and institutional data security requirements, with access restricted to authorized study personnel.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .